



Arseus realises successful IPO at €10.25 per share

The Offering was approximately 2 times oversubscribed

Waregem, October 4, 2007 - Arseus NV, the professional healthcare division of Omega Pharma, has successfully completed its initial public offering (IPO). The Offering was approximately 2 times oversubscribed at an Offer Price of €10.25 per share. The Shares, VVPR strips and Offering Warrants will be listed as of tomorrow, October 5, on Eurolist by Euronext Brussels. The Shares will also be traded on Eurolist by Euronext Amsterdam.

Pursuant to the Offering, Omega Pharma sold 20,468,144 existing shares for a total amount of €209.8 million. Additionally, 6,000,000 new shares were issued, raising a total of €61.5 million in gross proceeds. An over-allotment option of 2,968,144 existing shares has been granted. The total amount of allocated shares thus amounts to 26,468,144 which, at the final IPO price of €10.25, corresponds to a total amount raised of €271 million.

The details with regard to the allocation of shares to retail investors will be published in the Belgian financial press on Friday, October 5, 2007 and will be announced on the websites of Arseus and Omega Pharma as well as the Belgian syndicate banks.

Arseus profile

Arseus generated a turnover of € 277 million in 2006, with 1,230 staff members. Arseus supplies healthcare professionals, on a European level, with products and services that enable them to provide high-quality services in an efficient manner. Arseus services pharmacists, general practitioners, specialist physicians, dentists, eye care professionals, nursing staff as well as hospitals and elderly care homes. Ageing population and the growing consumer awareness for health, well-being and aesthetics lead to a strong growth market for Arseus.

Enquiries:

Arseus

Ger van Jeveren, Chief Executive Officer
Jan Peeters, Chief Financial Officer

Tel: +32 56 62 88 00

Omega Pharma

Chris Van Raemdonck

Tel: +32 9 381 03 31

The Offering and the distribution of the Prospectus and this press release may be restricted by law in certain jurisdictions outside Belgium. Arseus does not represent that the Prospectus or this press release may be lawfully distributed in jurisdictions outside Belgium or that the Shares, VVPR strips or Offering Warrants may be lawfully offered in compliance with any applicable registration or other requirements in jurisdictions outside Belgium, or pursuant to any exemption available thereunder. Arseus does not assume any responsibility for such distribution or offering. Accordingly, the Shares, VVPR Strips or Offering Warrants may not be offered or sold, directly or indirectly, and neither the Prospectus, this press release nor any advertising or other offering materials may be distributed or published in any jurisdiction outside Belgium, except in circumstances that will result in compliance with any applicable laws and regulations. The Prospectus does not constitute an offer to sell or a solicitation of an offer to buy any of the securities to any person in any jurisdiction in which it is unlawful to make such offer or solicitation to such person. Persons in whose possession the Prospectus or any of the securities come, must inform themselves about, and observe any such restrictions.

The Offered Shares have not been and will not be registered under the Securities Act of the USA. Subject to certain exceptions, the securities may not be offered, sold or delivered in the United States of America (USA), or to, for the account or benefit of, US persons, except in certain transactions exempt from the registration requirements of the Securities Act. The terms used in this paragraph have the meanings given to them by Regulation S. The Shares, VVPR Strips and Offering Warrants have not been approved or disapproved by the USA Securities and Exchange Commission, any state securities commission in the USA or any other USA regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the securities or the accuracy or adequacy of the Prospectus. Any representation to the contrary is a criminal offence in the USA.